Fig. 3
From: High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer
Cancer types investigated in 34 published and 23 ongoing (status February 2021) VitC clinical trials. Annotated are VitC dose group (A and C; high dose ≥1 g/kg, low dose ≤10 g whole body dose) and treatment type (B and D). See Table 2 (medium-to-high-dose published trials; 16/34 of total published trials) and Table 3 (medium-to-high dose ongoing trials; 16/23 of total ongoing trials) for details